Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Urinary Bladder Neoplasms 1Ureteral Neoplasms 1Rare Diseases 1Paraproteinemias 1Neuromyelitis Optica 1Neurologic Manifestations 1Nervous System Diseases 1Neoplasms, Plasma Cell 1Myelitis, Transverse 1Myasthenia Gravis 1Multiple Sclerosis 1Multiple Myeloma 1Mental Disorders 1Kidney Diseases 1Hematologic Diseases 1Encephalomyelitis, Acute Disseminated 1Diffuse Cerebral Sclerosis of Schilder 1Autoimmune Diseases 1Acute Kidney Injury 1

Interventions

Metformin 2Leuprolide 2Collagenases 2Clomiphene 2tremelimumab 1durvalumab 1Temozolomide 1Streptozocin 1Spironolactone 1Specimen Handling 1Radiosurgery 1Radiation 1Propofol 1Prednisone 1Plasma Exchange 1Nivolumab 1Midazolam 1Mercaptopurine 1Melphalan 1Magnetic Resonance Spectroscopy 1Irinotecan 1Ipilimumab 1Infliximab 1Immunoglobulins 1High-Throughput Nucleotide Sequencing 1Fentanyl 1FANG vaccine 1Cyclophosphamide 1Clomipramine 1Carmustine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Rare Diseases × Plasma Exchange × Clear all
NCT00004645 2005-06-24

Phase III Randomized, Double-Blind, Sham-Controlled Study of Plasma Exchange for Acute Severe Attacks of Inflammatory Demyelinating Disease Refractory to Intravenous Methylprednisolone

Office of Rare Diseases (ORD)

Phase 3 Unknown
22 enrolled

Mental Disorders, Diffuse Cerebral Sclerosis of Schilder, Encephalomyelitis, Acute Disseminated, Multiple Sclerosis, Myelitis, Transverse, Neurologic Manifestations, Neuromyelitis Optica, Rare Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡